China’s Tot Biopharm Secures First Antibody Approval With Avastin Biosimilar
Regulator NMPA Approves Pusintin Biosimilar Product For Cancer Indications
After listing on the Hong Kong stock exchange in late 2019, China’s Tot Biopharm has delivered its first antibody drug approval, with its Pusintin (bevacizumab) biosimilar to Avastin.
You may also be interested in...
Henlius Gets Fourth Chinese Biosimilar With Bevacizumab Nod
Shanghai Henlius Biotech has celebrated its fourth Chinese biosimilar approval with the NMPA’s endorsement of its bevacizumab biosimilar. The company is also working on an ophthalmic version to treat wAMD.
Two Chinese IPOs Kickstart A Hectic Biotech Fundraising Season
Two IPOs and 12 venture capital and private equity deals in China raised a combined $1bn in a hectic few weeks of October.
Asia Deal Watch: Heartseed Licenses Lead Cell Therapy Candidate To Novo Nordisk
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.